✦ LIBER ✦

Phase II evaluation of suramin in advanced renal cell carcinoma: A Southwest Oncology Group study

✍ Scribed by Louis E Schroder; Danika Lew; Robert C Flanigan; Mario A Eisenberger; Thomas E Seay; Neel Hammond; Burton M Needles; E.David Crawford

Book ID: 117724123
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 51 KB
Volume: 6
Category: Article
ISSN: 1078-1439
DOI: 10.1016/s1078-1439(00)00126-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II evaluation of mitoxantrone in a

Phase II evaluation of mitoxantrone in advanced pancreatic carcinoma: A Southwest Oncology Group study

✍ Sarah A. Taylor; Thomas Fleming; Daniel D. Hoff; Joseph D. McCracken; Ronald M. 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 242 KB

Patient with advanced adenocarcinoma of the pancreas and no prior chemotherapy were treated on a Phase II trial of mitoxantrone. Doses were adjusted for hepatic dysfunction as defined by bilirubin. Twenty-four patients with a bilirubin less than or equal to 1.5 mg% received mitoxantrone 12 mg/m2 i.v

A phase II study of flavopiridol in pati

A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109

✍ Peter J. Van Veldhuizen; James R. Faulkner; Primo N. Lara; Paul H. Gumerlock; J. 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 217 KB

Phase II evaluation of bleomycin. A Sout

Phase II evaluation of bleomycin. A Southwest Oncology Group study

✍ Charles D. Haas; Charles A. Coltman Jr.; Jeffrey A. Gottlieb; Arthur Haut; James 📂 Article 📅 1976 🏛 John Wiley and Sons 🌐 English ⚖ 369 KB 👁 2 views

Bleomycin given intravenously (i.v.) or intramuscularly (i.m.) in twice-weekly doses of 10 mg/mz was evaluated for efficacy and toxicity in 382 patients. Responses were observed in 11/27 Hodgkin's diseases, 10/30 lymphomas, 9/22 squamous cell cancers of ectodermal origin, 12/26 germinal cancers, and

A phase II trial of interferon-α and 5-f

A phase II trial of interferon-α and 5-fluorouracil in patients with advanced renal cell carcinoma: A Southwest Oncology Group study

✍ Laurence Elias; Brent A. Blumenstein; Julie Kish; Robert C. Flanigan; James L. W 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 355 KB 👁 1 views

## BACKGROUND. Renal cell carcinoma is a common neoplasm that is often refractory to treatment. It is occasionally responsive to immunoniodulating agents including interferon-a, which enhances the effects of 5-fluorouracil upon cells. Combinations of these two drugs have been most frequently tested

Phase II trial of carboplatin and paclit

Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma : A Southwest Oncology Group study

✍ Ulka N. Vaishampayan; James R. Faulkner; Eric J. Small; Bruce G. Redman; Wayne L 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

## Abstract ## BACKGROUND The purpose of the study was to assess the efficacy and toxicity of carboplatin and paclitaxel administered every 3 weeks in patients with advanced urothelial carcinoma, previously treated with cisplatin‐based therapy. ## METHODS Eligibility included metastatic or local

Evaluation of fludarabine phosphate in s

Evaluation of fludarabine phosphate in small cell carcinoma. A Southwest Oncology Group study

📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 155 KB